Abstract
The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.
| Original language | English |
|---|---|
| Pages (from-to) | 255-258 |
| Number of pages | 4 |
| Journal | Bone |
| Volume | 50 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2012 |
Fingerprint
Keywords
- Antiviral treatment
- Bone alkaline phosphatase
- C-terminal telopeptide of type I collagen
- HIV
- Infants
- Quantitative ultrasonography
ASJC Scopus subject areas
- Physiology
- Endocrinology, Diabetes and Metabolism
- Histology
Cite this
Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. / Mora, Stefano; Giacomet, Vania; Viganò, Alessandra; Cafarelli, Laura; Stucchi, Sara; Pivetti, Valentina; Manfredini, Valeria; Puzzovio, Maria; Zuccotti, Gianvincenzo.
In: Bone, Vol. 50, No. 1, 01.2012, p. 255-258.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Exposure to antiretroviral agents during pregnancy does not alter bone status in infants
AU - Mora, Stefano
AU - Giacomet, Vania
AU - Viganò, Alessandra
AU - Cafarelli, Laura
AU - Stucchi, Sara
AU - Pivetti, Valentina
AU - Manfredini, Valeria
AU - Puzzovio, Maria
AU - Zuccotti, Gianvincenzo
PY - 2012/1
Y1 - 2012/1
N2 - The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.
AB - The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.
KW - Antiviral treatment
KW - Bone alkaline phosphatase
KW - C-terminal telopeptide of type I collagen
KW - HIV
KW - Infants
KW - Quantitative ultrasonography
UR - http://www.scopus.com/inward/record.url?scp=81255178826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81255178826&partnerID=8YFLogxK
U2 - 10.1016/j.bone.2011.10.030
DO - 10.1016/j.bone.2011.10.030
M3 - Article
C2 - 22080170
AN - SCOPUS:81255178826
VL - 50
SP - 255
EP - 258
JO - Bone
JF - Bone
SN - 8756-3282
IS - 1
ER -